Viewing Study NCT03510104



Ignite Creation Date: 2024-05-06 @ 11:25 AM
Last Modification Date: 2024-10-26 @ 12:44 PM
Study NCT ID: NCT03510104
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2023-10-11
First Post: 2018-04-16

Brief Title: Pharmacokinetic and Safety Study of MRX-2843 in Adults With RelapsedRefractory Advanced andor Metastatic Solid Tumors
Sponsor: Meryx Inc
Organization: Meryx Inc

Study Overview

Official Title: A Phase I Dose Escalation Study of the Safety Pharmacokinetics and Pharmacodynamics of MRX-2843 in Adult Subjects With RelapsedRefractory Advanced andor Metastatic Solid Tumors
Status: ACTIVE_NOT_RECRUITING
Status Verified Date: 2023-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This first-in-human open-label dose escalation study is designed to evaluate the safety tolerability and PK of MRX-2843 in subjects with relapsedrefractory advanced andor metastatic solid tumors
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None